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Abstract.
BACKGROUND: Millions of people are treated with antidepressants like selective serotonin reuptake inhibitors (SSRIs) or
serotonin-norepinephrine reuptake inhibitors (SNRIs). This clinical practice is based on short-term trials that have exaggerated
the benefits and underestimated the harms. We also know too little about long-term harms.
AIM: To assess harms of SSRIs and SNRIs that persist after end of drug intake.
METHODS: Systematic review of placebo-controlled randomised trials of any length in patients with a psychiatric diagnosis
and a follow-up of at least six months. Our primary outcomes were mortality, functional outcomes, quality of life and core
psychiatric events. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials and checked the
references for eligible articles. One researcher extracted data and another checked the data extraction.
RESULTS: Our searches returned 9,153 unique records. We included 22 papers for 12 trials on SSRIs. Median intervention
and follow-up periods were 15 and 52 weeks, respectively. Median number of randomised participants was 51; only two
trials had a drop-out rate below 20%.
Outcome reporting was less thorough during follow-up than for the intervention period and only two trials maintained the
blind during follow-up. All authors concluded that the drugs were not beneficial in the long term.
All trials reported harms outcomes selectively or did not report any. Only two trials reported on any of our primary outcomes
(school attendance and number of heavy drinking days).
CONCLUSION: The randomised trials currently available cannot be used to investigate persistent harms of antidepressants.
Keywords: SSRI, harms, long-term, antidepressants, SNRI
1. Background
The number of people treated with psychiatric drugs is increasing [1–5]. Sales of selective serotonin
reuptake inhibitors (SSRIs) and similar antidepressants are estimated to be so high in Denmark, that
every seventh citizen can be treated with such a drug for their entire life [6].
There are many problems with placebo controlled trials of antidepressants [6–8]. The trials are of
short duration, a median of only 9 weeks [8]; withdrawal effects are almost always introduced in
the placebo group because the patients were already in treatment before they were randomised; lack
of effective blinding; attrition; and selective reporting of major harms [6–8]. Published papers have
therefore exaggerated the benefits and underestimated the harms.
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Despite these difficulties, we do know that short term use of antidepressants can cause irritability,
anxiety and panic, emotional flattening, dyskinesias [9], sexual impairment [10, 11] and also suicidality
and aggression [8], even in healthy adult volunteers [12]. In observational studies, antidepressants
have been linked to increased risk of dementia [13]; they may induce depressogenic effects; and
the prevalence of treatment-resistant depression appears to be increasing [14]. Antidepressants have
stimulant effects and rather than acknowledging this drug harm, it has led to a diagnosis of bipolar
disorder in about 10% of children aged 10–14 years under the care of mental health services [15],
which is a far worse disease than depression and is often treated with antipsychotics. Similar results
have been reported for adults [16].
Despite the fact that we base our clinical practice on short-term trials, many patients continue on the
drugs for years. A major reason for this is that they have difficulty coming off the drugs again because
of withdrawal effects [17, 18], which for SSRIs are very similar to those the patients experience when
they try to stop benzodiazepines [19].
Long-term use of psychiatric drugs may cause permanent brain damage, which has been most
clearly documented for antipsychotics [20, 21]. Animal studies have shown that prenatal exposure to
psychiatric drugs can lead to altered physiology and behaviour later in life [22, 23].
We therefore decided to do a systematic review of long-term, or persistent, harms of treatment with
SSRIs or serotonin-norepinephrine reuptake inhibitors (SNRIs) after at least six months follow-up
after end of a drug treatment in humans.
2. Methods
2.1. Type of studies
We included randomised, placebo-controlled trials with a parallel group design that compared
antidepressant drugs with placebo. There were no language restrictions.
2.2. Participants
Participants of all ages with a psychiatric diagnosis were eligible.
2.3. Type of interventions
Trials of any length comparing SSRIs or SNRIs as monotherapy to placebo were accepted, if the
follow-up period from end of drug treatment was at least six months. We also accepted trials where at
least a six-month follow-up included a tapering period.
Trials allowing concomitant medication or psychosocial interventions in both groups were accepted.
Wash-out periods or placebo lead-in phases were noted. We also noted to what extent drugs are
administered for side effects during follow-up, as this could potentially conceal the lasting harms of
the study drugs.
2.4. Primary outcomes
We extracted data at the end of follow-up. Validated scales were preferred over non-validated scales.
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2.5. Our primary outcomes
1. Death.
2. Functional outcomes, e.g. job adherence, marital status, delinquency and traffic accidents.
3. Quality of life.
4. Core psychiatric events [24] – as listed in Appendix A.
2.6. Secondary outcomes
◦ Admission to hospital.
◦ Relapse/recovery rates.
◦ Sexual dysfunction.
◦ Self-rated symptom scores.
◦ Serious adverse events.
◦ Adverse events were listed under primary outcomes or serious adverse events; arbitrary thresholds
for reporting were noted.
◦ Cognitive function, including dementia – measured on psychometric scales.
2.7. Data collection, extraction and analysis
Database searches were done in PubMed, Embase and the Cochrane Central Register of Controlled
Trials (CENTRAL) for psychiatric drugs in general (Appendix B). For additional information on
harms, we looked up the included trials in www.clinicaltrials.gov and www.clinicaltrialsregister.eu.
Screening of titles and abstracts were done by one assessor (PD). When in doubt, a second observer
(PG) was involved. As our data searches were very broad (see Appendix B), we lowered the number
of articles to screen by including only those abstracts that contained the word ‘placebo’ in Endnote,
and we also excluded abstracts that contained the word ‘anesthesia’, as trials that tested psychiatric
drugs for their anesthetic properties had inadequate drug-free follow-up periods.
Possibly eligible articles were read in full by two observers independently (PD and MV) who assessed
their eligibility. One observer (PD) extracted data from the articles, which were checked by another
observer (PG). Any disagreements were resolved by discussion. We reviewed the reference lists of the
included papers, and if necessary, we contacted the authors of the studies to obtain more information.
We assessed the risk of bias according to the Cochrane Handbook [25] and added sponsorship bias.
We also included co-morbidity bias and responder selection bias, as described in the protocol for a
Cochrane review on methylphenidate in adults [26].
We performed a systematic review and had planned to perform meta-analyses but this was not
possible.
3. Results
Our database searches identified 9153 unique records for psychiatric drugs. After screening of titles
and abstracts, 262 records remained, and after full text reading we identified 40 papers with SSRIs or
SNRIs as intervention drugs regardless of the indication, 22 of which were included, as they addressed
participants with a psychiatric disorder. The 22 papers represented 12 unique trials (see PRISMA flow
chart in Appendix B). The median publication year for the primary publication of the trials was 2013
(range 1990 to 2016).
All trials had studied SSRIs, which were fluoxetine [27–30], fluvoxamine [31–33], sertraline [34,
35], escitalopram [36, 37] and paroxetine [38] (see Table 1 for details of the trials). For three trials the
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doses were fixed [27, 32, 38], while the remaining trials titrated the dose. The trials aimed at relieving
the trial participants for symptoms of depression, post-traumatic stress disorder, obsessive-compulsive
disorder, panic disorder, binge eating disorder, school refusal with anxiety and benzodiazepine use
in depression. Two trials were carried out in adolescents [28, 29], while the remaining trials were in
adults.
The median intervention period was 15 weeks (range 7 to 32 weeks), and the median follow-up after
the randomised phase was 52 weeks (range 24 to 364 weeks) for 11 trials; the remaining trial [38]
accepted varying follow-up periods ranging from four to 211 weeks). Seven trials were registered in
an online trial register, and two of those had registered study results [30, 35].
The median number of participants randomized to the interventions was 51 (range 31–300). The
median drop-out rate was 22% (range 10% to 52%) among the 11 trials that provided numbers. The
median drop-out rate at end of follow-up was 26% (range 12% to 50%) among the nine trials that
provided numbers. Only two trials had a drop-out rate below 20% [33, 37]. The median percentage of
male participants was 40 (range 19 to 66) for the eleven studies with information.
The tapering method was specifically described for three trials; in one, the medication was stopped
abruptly [30], and two described a four-week [31] and a six-week taper [32], respectively. The remaining
trials either just mentioned a taper [28, 35, 36], or did not mention it at all.
3.1. Risk of bias assessments
For sequence generation, the risk of bias was low for six trials [28, 34–38] and for allocation
concealment, it was low for seven trials [28, 30, 34–38]. During the randomised phase, blinding of
participants and personnel was maintained for five trials [30, 31, 34, 35, 37] and for the outcome
assessors for eight trials [28, 30, 31, 33–35, 37, 38].
For blinding during the follow-up, the risk of bias amongst observers was low in two trials [30,
31], as the observers were blind to treatment conditions throughout the trial. Five trials had an unclear
risk of bias, as it was not clear whether the blinding was maintained during follow-up [29, 34–37],
whereas the remaining five trials had a high risk of bias because the blind was broken at the end of the
intervention.
All trials reported harms outcomes selectively or did not report any. Primary outcomes as described
in our methods section were only reported by two trials; one reported on school attendance [28] and
the other on number of heavy drinking days [35]. For the secondary outcomes, three trials reported on
remitters [27, 30, 34], and one trial reported on the self-rated Visual Analogue Scale for Depression [37].
Two trials were sponsored by both public and private grants [32, 36], one trial stated in the trial
register that a medical centre in Israel was the sponsor but in the paper Lundbeck was the funder of
the trial [37]. Two trials had no information on funding [29, 33]; the remaining trials were publicly
funded. Three publicly funded trials disclosed conflicts of interest of the authors [30, 35, 38] who
were either employed in a drug company or functioned in advisory boards or as consultants for drug
companies. One trial declared no conflicts of interest but was both publicly and privately funded [36];
the remaining trials shared no information on conflicts of interest.
We assessed whether co-morbidities were allowed so that the results from the clinical trials could
be extrapolated to clinical practice. The risk of bias was high for all trials, as only participants with
no or little co-morbidity were included. Furthermore, all trials were biased in relation to the way the
participants were recruited. No trials clearly listed the participants as being treatment-naı¨ve and seven
trials explicitly reported to have used either a placebo lead-in or a drug wash-out period before the
randomisation [29–33, 35, 38]. Two trials did not exclude patients based on their previous responses
to antidepressant drugs [28, 33]; two trials did not report on this [27, 36], while the remaining trials
excluded patients based on their history or response to drugs, placebo or therapy.
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3.2. Outcome reporting
The reporting of harms was inadequate in all the trials. Three trials had used a scale for a systematic
collection of adverse events: the 36-item somatic symptom check list [34], the Fawcett scale [32], and
the 58-item side effects for children and adolescents scale [28]. For the trials that predefined the use
of scales, adverse events were reported for the intervention period if there were statistically significant
differences between groups and no adverse events were mentioned for the follow-up [34]; adverse
events were reported if they were common (difficulty falling asleep or waking up, anger outbursts,
headache, irritability, lethargy, apathy, non-suicidal self-injury ideation) [28]; or adverse events were
not reported at all [32]. Two additional trials provided tables of adverse events during follow-up with
no mention of choice of scale: one provided a table of serious adverse events in a trial register [35],
and one provided a table of seven adverse events in the paper [37]. In summary, only three trials
reported adverse events collected during follow-up [28, 35, 37] and we do not know if the reporting
was complete.
The reporting of outcomes for the follow-up periods was not as thorough as the reporting for the
intervention periods. One study reported that fluoxetine had a positive influence on school attendance,
as ten participants (50%) in the fluoxetine group had more than 80% school attendance at end of
follow-up compared to four participants (25%) in the placebo group [28], but several other outcomes
assessed did not show statistically significant differences between groups. Based on the findings and
conclusions by the authors, all trials stated that the intervention drug had not been superior to placebo,
when participants were assessed at the end of follow-up, although a few among many outcomes found
the tested drug to be superior [28, 33–36].
4. Discussion
It is well known that harms caused by SSRIs can be long-lasting [18] and there are indications that
they can even be permanent, e.g. for sexual disturbances [39, 40]. Withdrawal symptoms are also drug
harms, and they can also persist for a long time [18].
Even though the median publication year was 2013, and even though all the trials we reviewed had
a follow-up of at least 24 weeks after the randomised phase, none of them reported adequately on
persisting harms of SSRIs; in fact, the reporting was very poor and selective. The authors were not
even interested in reporting withdrawal effects although they likely occurred in all the trials.
Two trials reported on our pre-defined primary outcomes [28, 35]. As noted above, school attendance
was higher for previously treated adolescents compared to placebo recipients [28], but given the number
of trials and outcomes, this is likely a chance finding. For heavy drinking days there was no difference
between drug and placebo at end of the 12-month follow-up [35]. For our secondary outcomes, data
were sparsely reported for the follow-up periods and therefore useless. Thus, the outcomes that are
relevant to the patients were almost universally ignored. Based on the reported effect outcomes, the
SSRIs seemed to be no better than placebo at follow-up, also in the original authors’ opinion. This is
possibly an understatement, as the harms reporting was insufficient. In fact, it has been shown, based
on clinical study reports obtained from the European drug regulators, that 12% more patients drop out
during the randomized phase when they are on drug than when they are on placebo [41]. This suggests
that placebo is a better pill than an antidepressant drug because the patients weigh the benefits against
the harms when they decide whether to stay in a trial or to drop out.
A search on PubMed (31 May 2018) on “antidepressants AND placebo” limited to the article type
“Randomized Controlled Trial” yielded 5,233 references. Thus, it seems that none of the authors of
the thousands of placebo-controlled trials have been interested in finding out what the more lasting
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harms are of treatment with antidepressant agents. This is very worrying, particularly considering that
the patients often complain about harms long after they have come off the drugs [18, 40, 42].
Since the randomised trials are not helpful, we need to look at observational studies instead. A US
national sample (n = 15,365) with a 9-year follow-up found that patients medicated for symptoms of
major depressive disorder (measured on several parameters like the Instrumental Activities of Daily
Living and the Composite International Interview short-form) had poorer long-term outcomes, based
on symptom severity, than those who were not treated or used treatment other than medication [43].
Symptom severity could not be explained by covariates such as initial disease severity.
Another indication that long-term treatment with psychiatric drugs is unlikely to be beneficial is
that, in all countries examined, the number of people on disability pension has gone up while usage of
psychiatric drugs has also gone up [44]. By far the most used drug category is antidepressants.
Inadequate reporting of harms, even serious harms like deaths, is a general problem for psychiatric
drug trials [6, 8, 45, 46], and the discrepancy between data in clinical study reports and in journal
publications is disturbing [7, 12, 47, 48]. This means that psychiatrists are unable to choose drug
treatment strategies that optimise the benefit-to-harm balance.
Compared to the above, the co-morbidity bias we found is of minor importance. The problem with
representativeness of the results from clinical trials have been highlighted before, e.g. in a study that
showed that only 41 of 346 (12%) outpatients would qualify for a clinical trial based on common
inclusion and exclusion criteria for antidepressant efficacy trials [49].
Responder selection bias is also related to the representativeness of clinical trials. In eight of the
included trials, there were problems related to this.
Conclusion
The currently available randomized trials are not helpful in elucidating what the persistent harms of
antidepressants drugs are.
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Appendix A – overview of psychiatric adverse events, as used in Bielefeldt et al.,
and Maund et al.
List of terms for suicidality, violence, and proposed driving mechanisms for these events
Table of terms were developed based on:
• FDA clinical review of the relationship between antidepressants and suicidality in adults
• Literature Review – Sinclair et al., Price et al. and reference checking
• Email and teleconference with Professor David Healy
Suicidality DH comments
Core event
Accident
Attempt
Burn
Cut
Drown
Gas
Gun
Hang
Hung
Immolat
Injur
Jump
Monoxide
Mutil
Overdose
Salf damage
Self harm
Self inflicted
Self injury
Shoot
Suici
(Continued)
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(Continued)
Suicidality DH comments
Poison
Asphyxiation
Suffocation
Firearm
Violence Synonyms DH comments
Core event
Homicide
Physical assault Assaultive behaviour
Physical abuse
Homicidal ideation
Violence-related symptom Criminal behaviour,
Antisocial behaviour,
Physically threatening behaviour
Activation event Synonyms DH comments
Core event
Jitteriness Jittery
Shakiness Inner shakiness Should be included as core event
Irritability Increased irritability, hostility, frustration Should be included as core event
Increased energy Increased energy, excessive energy,
unusual energy, feeling euphoric,
euphoria, CNS stimulation,
overstimulation, caffeine feeling,
amphetamine speed like response, racing
thoughts
Mania (also listed under
psychotic event)
Hypomania Drs may use mania for both activation and
psychotic events. Patients report being
“manic” when they mean more active than
normal i.e. experiencing activation.
Anxiety Increased anxiety, overanxious,
nervousness, anxiety attack
Agitation Increased agitation, aggression, hostility,
argumentative
Restless Restlessness, motor restlessness,
fidgetiness, hyperactivity, hyperkinesia,
“skin crawling”
Akathisia
Potential event
Insomnia Insomnia, sleeplessness, Not really an activation symptom
Tremor Trembling Should be a potential event
Panic Panic attack, panic symptoms
Tension Tension increased, tenseness
Unable to relax
Easily startled
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Psychotic event Synonyms DH comments
Core event
Hallucinations
Paranoia
Feelings of doom
Delusions
Delirium
Psychosis
Abnormal thinking Intrusive thoughts, unusual thoughts,
abnormal feelings
Confusion Disorientation, incoherent thoughts Comment EM: “spaciness” was a verbatim
term being coded as confusion in tables for
SER trials but DH said verbatim term of
“spaciness” should be considered emotional
disturbance
Behavioural dyscontrol
Manic reaction (also listed Hypomania, euphoria
under activation)
Hysteria
Potential event
Nightmares Bad dreams
Abnormal dreams Strange dreams, increased dreams, vivid
dreams, intense dreams
Emotional disturbance Synonyms DH comments
Core event
Flat effect Flattened, reduced ability to feel positive
emotions, feeling blank
Apathy Indifference
Anhedonic
Disinhibition
Depersonalised
Derealisation Depersonalisation This is not an especially psychotic event and
belong with emotional disturbance
Emotionally detached
Lack of empathy
Impulsivity
Emotional lability
Spaciness
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Appendix B – flow diagram and information on searches
P.B. Danborg et al. / Long-term harms from previous use of SSRIs 71
Information on searches
For PubMed and Embase:
Filters applied: ‘Randomized Controlled Trial’ and ‘Humans’
For indexed MeSH/Map terms, we will restrict to Major Topic (PubMed) and Focus (Embase) to
include studies with main focus on the selected topic for the drug categories.
All databases:
Narrowing down to trials with follow-up we will apply the following terms: “Follow-Up
Studies”[MeSH], discontinuation[tiab], maintenance[tiab], follow-up[tiab], long-term[tiab], with-
drawal[tiab], extension[tiab], substance withdrawal syndrome[MeSH].
[tiab] searches in PubMed are equivalent to.mp searches in Embase and :ti,ab searches in CENTRAL.
Equivalent searches were applied in the three databases.
Example, PubMed search categories, MeSH:
“Anti-Anxiety Agents” [Pharmacological Action]
“Anticonvulsants” [Pharmacological Action]
“Barbiturates”[Mesh]
“Serotonin Uptake Inhibitors” [Pharmacological Action]
“Antidepressive Agents” [Pharmacological Action]
“Monoamine Oxidase Inhibitors”[Mesh]
“Benzodiazepines”[Mesh]
“Antipsychotic Agents” [Pharmacological Action]
“Guanfacine”[MeSH]
“Clonidine”[Mesh]
“Hypnotics and Sedatives” [Pharmacological Action]
“Propylamines”[Mesh] incl atomoxetine and fluoxetine
“Central Nervous System Stimulants” [Pharmacological Action] incl. methylphenidate and guan-
facine, amphetamine, lisdexamphetamine, pemoline, modafinil (tested but rejected for ADHD)
“Tranquilizing Agents”[Mesh]
+text words [tiab/.mp/:ti,ab]: SSRI, antidepressant, methylphenidate, anticonvulsant, benzodi-
azepine, antipsychotics
For Embase search: explode-function and include all subheadings-function was applied to include
subgroups.
